Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy
Radioligand theranostics (RT) in oncology use cancer-type specific biomarkers and molecular imaging (MI), including positron emission tomography (PET), single-photon emission computed tomography (SPECT) and planar scintigraphy, for patient diagnosis, therapy, and personalized management. While the d...
Saved in:
Main Authors: | Cristina Barca (Author), Christoph M. Griessinger (Author), Andreas Faust (Author), Dominic Depke (Author), Markus Essler (Author), Albert D. Windhorst (Author), Nick Devoogdt (Author), Kevin M. Brindle (Author), Michael Schäfers (Author), Bastian Zinnhardt (Author), Andreas H. Jacobs (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms
by: Melpomeni Fani, et al.
Published: (2017) -
AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications
by: Cyril Fersing, et al.
Published: (2022) -
Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy
by: Cyprine Neba Funeh, et al.
Published: (2023) -
Radiopharmaceuticals for Treatment of Adrenocortical Carcinoma
by: Kerstin Michalski, et al.
Published: (2023) -
Dose-Dependent Internalization and Externalization Integrity Study of Newly Synthesized Tc-Thymoquinone Radiopharmaceutical as Cancer Theranostic Agent
by: Saima Tariq, et al.
Published: (2020)